BioTuesdays
AIM ImmunoTech

Maxim ups AIM ImmunoTech PT to $5 from $2

Maxim Group raised its price target for AIM ImmunoTech (NYSE American:AIM) to $5 from $2, citing a strengthened balance sheet and a $14.54-million award from the NCI to study its Ampligen drug candidate in up to five...

IDEAYA Biosciences Logo

HCW starts IDEAYA Biosciences at buy; PT $13

H.C. Wainwright launched coverage of IDEAYA Biosciences (NASDAQ:IDYA) with a “buy” rating and $13 price target. The stock closed at $3.59 on April 3. Analyst Edward White writes that IDE196 is the company’s potent...

IntelGenx

IntelGenx adjusts VersaFilm business strategy

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) unveiled a series of initiatives aimed at helping the company address, and satisfactorily respond to, the complete response letter that it recently received from the FDA...

Imara

SVB Leerink starts Imara at OP; PT $25

SVB Leerink initiated coverage of Imara (NASDAQ:IMRA) with an “outperform” rating and $25 price target in 12 months. The stock closed at $15.75 on April 3. Imara is focused on developing and commercializing novel...

Molecular Partners

HCW starts Molecular Partners at buy; PT CHF29

H.C. Wainwright initiated coverage of Swiss-based Molecular Partners (SWX:MOLN) with a “buy” rating and price target of CHF29. The stock closed at CHF17.54 on April 1. Molecular Partners is developing targeted therapies...

Chembio Diagnostics

Canaccord ups Chembio Diagnostics PT to $10 from $7

Canaccord Genuity raised its price target for Chembio Diagnostics (NASDAQ:CEMI) to $10 from $7, citing the launch of its 15-minute dual path platform (DPP) COVID-19 serology test in the U.S. The stock closed at $7.16 on...

Profound Medical

Cowen starts Profound Medical at OP; PT $15 (U.S.)

Cowen launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with an “outperform” rating and $15 (U.S.) price target. The stock closed at $9.74 on March 31. “[Profound’s] TULSA-PRO is a proprietary platform that...